Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Tab. CoReach: Tab. CoReach is a mixture of herbs which can be useful in treating Covid 19. Standard of care will be given in addition to the IP.
Control Intervention1: Standard of care:
and NSAIDs like Tab. Paracetamol. Dose: Standard adult dose of corresponding drugs. Route: Oral. Duration: 10 days.
Sponsors
Questt Clinicals and Ayurceuricals Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: I. Patients with laboratory confirmation of infection with SARS CoV-2 by positive RT-PCR or Rapid Antigen Test with mild to moderate symptoms (Mild: Upper respiratory tract symptoms (& or fever) WITHOUT shortness of breath or hypoxia Moderate: Any one of: 1. Respiratory rate > 24/min, breathlessness 2. SpO2: 90% to Ref: AIIMS ICMR-COVID-19 National Task Force) Patients progressing from moderate to severe grade during treatment will be withdrawn from the study II. Age >18 and III. Voluntarily participation in the clinical trial and agreeing to follow study procedures IV. Not participating in any other interventional drug clinical studies before completion of the present study V. Ready to give medical data for assessments
Exclusion criteria
Exclusion criteria: I. Critical infection, defined as need for invasive ventilator support II. Inability to intake or tolerate oral medications. III. Known pregnant or lactating women IV. Persons with severe primary respiratory disease or other pneumonia V. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess percentage of patients with 2 points improvement or becoming asymptomatic (Grade 2 or less) on the modified ordinal scale for clinical improvementTimepoint: Day 4 | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of Tab. CoReach in getting RT-PCR negative status earlierTimepoint: -;Efficacy of Tab. CoReach in normalizing cytokinesTimepoint: -;Improvement in Oxygen saturationTimepoint: -;Incidence of adverse events and treatment emergent adverse events during treatment periodTimepoint: Throughout study | — |
Countries
India
Contacts
Public ContactDr Hrishikesh Rangnekar
Questt Clinicals and Ayurceuticals Pvt Ltd
Outcome results
None listed